FY2026 EPS Estimates for XOMA Royalty Increased by Analyst

XOMA Royalty Corporation (NASDAQ:XOMA) – Equities researchers at Leerink Partnrs lifted their FY2026 earnings per share (EPS) estimates for shares of XOMA Royalty in a research report issued to clients and investors on Thursday, August 14th. Leerink Partnrs analyst D. Risinger now forecasts that the biotechnology company will post earnings per share of $0.67 for the year, up from their prior forecast of $0.61. The consensus estimate for XOMA Royalty’s current full-year earnings is ($1.41) per share.

A number of other brokerages have also recently weighed in on XOMA. Zacks Research raised XOMA Royalty to a “hold” rating in a research report on Tuesday. Wall Street Zen upgraded XOMA Royalty from a “hold” rating to a “buy” rating in a report on Monday, August 11th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $104.00 target price on shares of XOMA Royalty in a research report on Wednesday, May 28th.

XOMA Royalty Trading Down 0.7%

Shares of NASDAQ:XOMA opened at $31.37 on Friday. The company has a current ratio of 4.88, a quick ratio of 5.54 and a debt-to-equity ratio of 1.41. The stock has a market capitalization of $379.26 million, a PE ratio of -20.24 and a beta of 1.00. XOMA Royalty has a 1 year low of $18.35 and a 1 year high of $35.00. The firm has a fifty day moving average price of $26.41 and a 200 day moving average price of $24.35.

XOMA Royalty (NASDAQ:XOMA) last posted its quarterly earnings results on Wednesday, August 13th. The biotechnology company reported $0.48 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.60. XOMA Royalty had a positive return on equity of 2.63% and a negative net margin of 27.57%. The company had revenue of $13.13 million during the quarter, compared to the consensus estimate of $9.39 million.

Hedge Funds Weigh In On XOMA Royalty

Institutional investors have recently modified their holdings of the company. GAMMA Investing LLC grew its holdings in XOMA Royalty by 1,063.8% in the 1st quarter. GAMMA Investing LLC now owns 1,734 shares of the biotechnology company’s stock valued at $35,000 after buying an additional 1,585 shares during the last quarter. Nuveen Asset Management LLC grew its holdings in XOMA Royalty by 3.8% in the 4th quarter. Nuveen Asset Management LLC now owns 14,363 shares of the biotechnology company’s stock valued at $377,000 after buying an additional 527 shares during the last quarter. Northern Trust Corp grew its holdings in XOMA Royalty by 1.5% in the 4th quarter. Northern Trust Corp now owns 91,181 shares of the biotechnology company’s stock valued at $2,396,000 after buying an additional 1,340 shares during the last quarter. Bank of America Corp DE grew its holdings in XOMA Royalty by 34.7% in the 4th quarter. Bank of America Corp DE now owns 7,796 shares of the biotechnology company’s stock valued at $205,000 after buying an additional 2,009 shares during the last quarter. Finally, Renaissance Technologies LLC raised its stake in XOMA Royalty by 89.8% during the 4th quarter. Renaissance Technologies LLC now owns 16,100 shares of the biotechnology company’s stock valued at $423,000 after purchasing an additional 7,619 shares during the last quarter. Institutional investors own 95.92% of the company’s stock.

Insider Activity at XOMA Royalty

In other news, CEO Owen Hughes sold 25,637 shares of XOMA Royalty stock in a transaction that occurred on Tuesday, May 20th. The shares were sold at an average price of $25.38, for a total value of $650,667.06. Following the transaction, the chief executive officer owned 62,701 shares of the company’s stock, valued at $1,591,351.38. This trade represents a 29.02% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 9.10% of the stock is currently owned by corporate insiders.

XOMA Royalty Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.